• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Pulmera wins FDA clearance for 3D imaging platform

Pulmera wins FDA clearance for 3D imaging platform

June 2, 2026 By Sean Whooley

Pulmera CBeam LogoPulmera announced today that it received FDA 510(k) clearance for its CBeam 3D intraoperative imaging platform.

Palo Alto, California-based Pulmera designed CBeam to transform conventional 2D surgical C-arms into intraoperative 3D imaging systems. The technology helps surgical teams visualize complex anatomy during procedures. It enables hospitals to expand access using imaging infrastructure they already own.

The company said it aims for CBeam to provide 3D imaging during orthopedic and neurological surgical procedures. These are procedures in which clinicians benefit from 3D visualization of anatomical structures. Those include high-contrast objects, bones, joints, maxillofacial anatomy, the cervical, thoracic and lumbar spine, pelvis, acetabulum. It also extends to fractures of the upper and lower extremities.

Pulmera designed its platform with a position-sensor-based system that attaches to widely installed surgical C-arms. It captures a series of X-ray images during a brief rotational scan and reconstructs them into a 3D dataset. This enables intraoperative visualization to support clinical evaluation, navigation and surgical decision-making.

The company says it could convert existing infrastructure into a distributed network of mobile 3D imaging systems. This could expand access to advanced intraoperative visualization across orthopedic, spine and related surgical procedures.

Commentary from Pulmera officials

Kevin McGann, Pulmera CEO, said:

“FDA clearance for the CBeam platform is a defining milestone for Pulmera and an important step toward expanding access to advanced intraoperative imaging. We built CBeam to help transform existing C-arm systems into accessible, efficient, and cost-effective 3D imaging solutions for hospitals, ASCs, and surgeons. This achievement validates our vision to bring advanced imaging directly into the operating room without requiring hospitals to invest in entirely new imaging infrastructure.”

Dr. Bryan Hartley, co-founder and chief product officer of Pulmera, said;

“As a standalone platform designed to unlock 3D imaging capabilities from existing C-arm infrastructure, CBeam reflects our commitment to practical innovation.”

Dr. Harmeet Bedi, co-founder, added:

“From the beginning, our mission has been to remove the traditional barriers that have limited access to advanced intraoperative imaging. FDA clearance is a powerful affirmation of years of innovation, persistence, and belief that surgeons deserve better tools without added complexity.

Filed Under: 510(k), Food & Drug Administration (FDA), Health Technology, Imaging, Regulatory/Compliance Tagged With: FDA, Pulmera

More recent news

  • Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
  • Autonomix taps former Medtronic FDA counsel head for board of directors
  • Medtronic strengthens robotic surgery position with Cornerstone deal, analysts say
  • Science Corp. names president as it looks to roll out vision-restoring implant
  • Mindray looks to fill hospital ventilator gap left by Philips’ exit

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy